Navigation Links
PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
Date:1/16/2012

SCHOFIELD, Wis., Jan. 16, 2012 /PRNewswire/ -- PuraMed BioScience, Inc. (OTCBB:PMBS) is pleased to announce the appointment of Sue A. Baacke, CPA, to the position of Chief Financial Officer.

Since 2009, Baacke has served as the Corporate Controller for PuraMed BioScience, Inc. gaining extensive experience in current SEC regulatory and compliance issues. Baacke came to PuraMed after holding a supervisory position at a well-established, Wisconsin-based, Certified Public Accounting firm for more than 12 years. Other experience includes auditing, preparation and review of financial statements, individual, corporate, and partnership income tax returns, payroll, and valuation of closely-held businesses.

Baacke's appointment allows PuraMed BioScience's former CFO / COO James Higgins to expand his role as chief operating officer.

"Our aim is to surpass the growth we have experienced during the last quarter through proficient management and development of our existing and new products as we continue to expand our national footprint and build our shareholder base," said Russ Mitchell, CEO of PuraMed BioScience. "We saw a need and an opportunity to strengthen our management team and we are pleased with this appointment."

Mitchell added, "Jim Higgins has done a stellar job for us as chief financial officer, and I look forward to his continued involvement as chief operating officer going forward."

About the PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products.  PuraMed has completed a double blind placebo clinical trial for its leading product, LipiGesic®M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. Please see the following link to view the abstract of that study. http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract.

LipiGesic®M has national distribution and is available nationwide in some of the largest chain drug stores in the United States. In addition to LipiGesic M, PuraMed BioScience, Inc also has plans to launch LipiGesic®H for tension-type headaches as well as LipiGesic®PM which provides a remedy for insomnia and other sleep disorders.

Forward-Looking Statements: 
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

 

Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
715-359-6373
rmitchell@PuramedBioScience.com
www.PuramedBioScience.com

Investor Relations:
Investor Awareness, Inc.
Tony Schor or James Foy
847-945-2222
www.investorawareness.com

 

 

 

 


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
2. Seahorse Bioscience, Inc. Appoints In Vitro Technologies Pty Ltd as New Distributor in Australia and New Zealand
3. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
4. Omeros Appoints David A. Mann to its Board of Directors
5. RainDance Technologies Appoints Olex Vice President, System Development
6. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
7. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
8. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
9. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
10. RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
11. UltraShape Appoints Assaf Eyal as President & CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
Breaking Biology News(10 mins):